Form 4 Filing for Randy H. Thurman - Outlook Therapeutics, Inc.

On May 26, 2026, Randy H. Thurman, a director at Outlook Therapeutics, Inc. (OTLK), acquired 5,000 shares of common stock through a purchase transaction at a price of $0.429 per share. Following this transaction, Mr. Thurman now directly owns 5,593 shares of OTLK common stock. The filing, designated as Form 4, was signed by Lawrence Kenyon as Attorney-in-Fact on May 27, 2026, and pertains to the reporting period ending May 26, 2026. This transaction indicates a director's investment in the company's stock.